EDAN(SZ:300206) Tai Ping Yang·2024-11-07 05:43Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative increase of over 15% compared to the CSI 300 index in the next six months [6][7]. Core Views - The i500 blood gas analyzer's market promotion is progressing smoothly, and the company is continuously advancing its digitalization layout [3][5]. - The company reported a revenue of 1.382 billion yuan for the first three quarters of 2024, a year-on-year decrease of 9.29%, with a net profit of 172 million yuan, down 27.42% year-on-year [3][5]. - The third quarter of 2024 saw a revenue of 460 million yuan, a year-on-year increase of 6.07%, and a net profit of 47 million yuan, up 57.15% year-on-year [3][5]. Financial Summary - The company expects revenues of 1.882 billion yuan in 2024, 2.109 billion yuan in 2025, and 2.349 billion yuan in 2026, with year-on-year growth rates of -2.89%, 12.06%, and 11.38% respectively [4][5]. - The projected net profit for 2024 is 224 million yuan, with expected growth rates of 1%, 19%, and 22% for the following years [4][5]. - The earnings per share (EPS) are forecasted to be 0.39 yuan in 2024, 0.46 yuan in 2025, and 0.56 yuan in 2026 [4][5]. Market Position and Strategy - The i500's launch is expected to solidify the company's leading position in the blood gas analysis field, addressing high-throughput analysis needs across various clinical departments [3][5]. - The company is actively promoting the i500 across the country and conducting beta testing, with progress aligning with company expectations [3][5]. - The report highlights the importance of digital health solutions, with the company integrating information technology into healthcare, supported by national policies [3][5].